Search results for: 'global 2014 2030'

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...

The microbiome sector is a core component of the self-care movement, promoting proactive health behaviors. The gut microbiota is now recognized as an organ-like system that influences overall health and specific medical conditions, making continued advancement critical to enhancing well-being.The consumer wellness industry is evolving alongside gro...

Medical imaging modalities such as X-ray imaging, magnetic resonance imaging, positron emission tomography, and others, have been designed to capture high resolution images through minimally-invasive approaches. However, each of these also suffer from limitations, foremost of which is that they utilize ionizing radiation that is hazardous to the pa...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

20 Nov 2017  |  North America  |  Market Research

Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

Infographics

×

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the gro...

16 Aug 2016  |  North America  |  Market Research

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Emerging Business Models Drive Transformation

Infographics

×

The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to comme...

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is stron...

19 Sep 2018  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022

Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics

Infographics

×

Key Issues Addressed

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global b...

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies towa...